- AstraZeneca shares slid on Monday despite positive news from the drugmaker’s first human COVID-19 vaccine trials.
- The early-stage human trial data for the vaccine – which is being developed in conjunction with Oxford University – showed the results of 543 vaccinated volunteers.
- The vaccine was able to generate immune responses in healthy volunteers, the results showed.
- In early US trade, the company’s stock was down by around 2.7%.
- Watch AstraZeneca trade …